MedTrace Logo

Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer

NCT01640730 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2014-01-16

No results posted yet for this study

Summary

This study is for patients with advanced non small cell lung cancer that has progressed despite standard of care. The purpose of the study is to see if Kanglaite injection has any effect on survival.

Conditions

  • Stage IV NSCLC

Interventions

DRUG

Kanglaite Injection

30gm IV infusion 5 days a week for 3 weeks every 28 days

Sponsors & Collaborators

  • KangLaiTe USA

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01640730 on ClinicalTrials.gov